The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | HCC at ESMO GI 2025: TACE plus IO, personalized biomarkers, & emerging therapies
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, reviews recent advances in liver cancer treatment presented at ESMO GI 2025. Prof. Lam Chan highlights the TALENTACE trial (NCT047126430), which confirms that combining TACE with systemic therapy, particularly immunotherapy, improves progression-free survival. In addition, Prof. Lam Chan stresses the importance of routine tumor biopsies to understand biology and baseline biomarkers for personalized treatment development, mentioning highly exploratory treatments including HDAC inhibitors, PPAR-alpha inhibition, and beta-catenin targeted therapies, noting that while clinical data is immature, promising results are expected within 5-10 years. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
